Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model

Gene Therapy

Volumn 16, Issue 8, 2009, Pages 973-981

  Yoon, K C ^a   Bae, J A ^b   Park, H J ^a   Im, S K ^a   Oh, H J ^a   Lin, X H ^a   Kim, M Y ^b   Lee, J H ^b   Lee, S E ^b   Ahn, K Y ^b   Kim, K K ^b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GA BINDING PROTEIN; GA BINDING PROTEIN ALPHA; GA BINDING PROTEIN BETA; LIPOPLEX; PLASMID DNA; ROUNDABOUT RECEPTOR; ROUNDABOUT RECEPTOR 4; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; DRUG MECHANISM; EPITHELIUM CELL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HISTOCHEMISTRY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; GA-BINDING PROTEIN TRANSCRIPTION FACTOR; GENE TRANSFER TECHNIQUES; HUMANS; INJECTIONS, INTRAOCULAR; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; RECEPTORS, IMMUNOLOGIC; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 69249213481     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.50     Document Type: Article

References (35)

1. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 and vascular endothelial growth factor in inflammation-associated corneal neovascularization. Exp Eye Res 2000; 70: 419-428.
2. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascualrization. Curr Opin Ophthalmol 2001; 12: 242-249.
3. Gabison E, Chang JH, Hernandez-Quintela E, Javier J, Lu PC, Ye H et al. Anti-angiogenic role of angiostatin during corneal wound healing. Exp Eye Res 2004; 78: 579-589.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
5. Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Therapy 2002; 9: 804-813.
6. Lai CM, Spilsbury K, Brankov M, Zaknich T, Rakoczy PE. Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp Eye Res 2002; 75: 625-634.
7. Campochiaro PA. Gene therapy for ocular neovascularization. Curr Gene Ther 2007; 7: 25-33.
8. Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV. Corneal gene therapy. J Control Release 2007; 124: 107-133.
9. Vázquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999; 274: 23349-23357.
10. Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002; 120: 1063-1068.
11. Wu PC, Liu CC, Chen CH, Kou HK, Shen SC, Lu CY et al. Inhibition of experimental angiogenesis of cornea by somatostatin. Graefes Arch Clin Exp Ophthalmol 2003; 241: 63-69.
12. Ma DH, Zhang F, Shi W, Yao JY, Hsiao CH, Wu HC et al. Expression of tissue inhibitor of metalloproteinase-4 in normal human corneal cells and experimental corneal neovascularization. Ophthalmic Res 2003; 35: 199-207.
13. Shafiee A, Penn JS, Krutzsch HC, Inman JK, Roberts DD, Blake DA. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest Ophthalmol Vis Sci 2000; 41: 2378-2388.
14. Shao C, Sima J, Zhang SX, Jin J, Reinach P, Wang Z et al. Suppression of corneal neovascularization by PEDF release from human amniotic membranes. Invest Ophthalmol Vis Sci 2004; 45: 1758-1762.
15. Dueñas Z, Torner L, Corbacho AM, Ochoa A, Gutiérrez-Ospina G, López-Barrera F et al. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Invest Ophthalmol Vis Sci 1999; 40: 2498-2505.
16. Yoon KC, Ahn KY, Lee JH, Chun BJ, Park SW, Seo MS et al. Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model. Gene Therapy 2005; 12: 617-624.
17. Rosmarin AG, Resendes KK, Yang Z, Mc Millan JN, Fleming SL. GA-binding protein transcription factor: A review of GABP as an integrator of intracellular signaling and protein-protein interactions. Blood Cells Mol Dis 2004; 32: 143-154.
18. Batchelor AH, Piper DE, de la Brousse FC, Mcknight SL, Wolberger C. The structure of GABPalpha/beta: An ETS domain-ankyrin repeat heterodimer bound to DNA. Science 1998; 279: 1037-1041.
19. Hauck L, Kaba RG, Lipp M, Dietz R, von Harsdorf R. Regulation of E2F1-dependent gene transcription and apoptosis by the ETS-related transcription factor GABPγ1. Mol Cell Biol 2002; 22: 2147-2158.
20. O'Leary DA, Koleski D, Kola I, Hertzog PJ, Ristevski S. Identification and expression analysis of alternative transcripts of the mouse GA-binding protein (Gabp) subunits alpha and beta1. Gene 2005; 344: 79-92.
21. Jeong BC, Kim MY, Lee JH, Kee HJ, Kho DH, Han KE et al. Brain-specific angiogenesis inhibitor 2 regulates VEGF through GABP that acts as a transcriptional repressor. FEBS Lett 2006; 580: 669-676.
22. Yang ZF, Mott S, Rosmarin AG. The Ets transcription factor GABP is required for cell-cycle progression. Nat Cell Biol 2007; 9: 339-346.
23. Okada Y, Yano K, Jin E, Funahashi N, Kitayama M, Doi T et al. A three-kilobase fragment of the human Robo4 promoter directs cell type-specific expression in endothelium. Circ Res 2007; 100: 1712-1722.
24. Bedell VM, Yeo SY, Park KW, Chung J, Seth P, Shivalingappa V et al Roundabout4 is essential for angiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 6373-6378.
25. Suchting S, Heal P, Tahtis K, Stewart LM, Bicknell R. Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J 2005; 19: 121-123.
26. Jones CA, London NR, Chen H, Park KW, Sauvaget D, Stockton RA et al Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nature Med 2008; 14: 448-453.
27. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37: 1625-1632.
28. Demir T, Celiker UO, Kükner A, Mogulkoç R, Celebi S, Celiker H. Effect of Octreotide on experimental corneal neovascularization. Acta Ophthalmol Scand 1999; 77: 386-390.
29. Knop E, Knop N. Anatomy and immunology of the ocular surface. Chem Immunol Allergy 2007; 92: 36-49.
30. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443: 993-997.
31. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: Therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004; 165: 2177-2185.
32. Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008; 27: 357-362.
33. Kim TI, Kim SW, Kim S, Kim T, Kim EK. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008; 27: 349-352.
34. You IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal noevascularization. Acta Ophthalmol 2009; 87 (in press).
35. Okada Y, Jin E, Nikolova-Krstevski V, Yano K, Liu J, Beeler D et al A GABP-binding element in the Robo4 promoter is necessary for endothelial expression in vivo. Blood 2008; 112: 2336-2339.